LQDA - iShares $ Corp Bond ETF USD Dist
After hours:
| Previous close | 8.59 |
| Open | 8.57 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's range | 8.45 - 8.74 |
| 52-week range | 3.38 - 8.99 |
| Volume | |
| Avg. volume | 445,369 |
| Market cap | 549.128M |
| Beta (5Y monthly) | 0.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.54 |
| Earnings date | 04 Nov 2021 - 08 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.29 |
Simply Wall St.Investing in Liquidia (NASDAQ:LQDA) a year ago would have delivered you a 106% gain
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...
- Simply Wall St.
Institutional investors are Liquidia Corporation's (NASDAQ:LQDA) biggest bettors and were rewarded after last week's US$60m market cap gain
Key Insights Institutions' substantial holdings in Liquidia implies that they have significant influence over the...
ZacksLiquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 0% and 8.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksStrength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
Liquidia Corporation's (NASDAQ:LQDA) Earnings Haven't Escaped The Attention Of Investors
You may think that with a price-to-sales (or "P/S") ratio of 28.5x Liquidia Corporation ( NASDAQ:LQDA ) is a stock to...
- Simply Wall St.
Industry Analysts Just Made A Captivating Upgrade To Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts
Liquidia Corporation ( NASDAQ:LQDA ) shareholders will have a reason to smile today, with the analysts making...
- Simply Wall St.
Liquidia Full Year 2022 Earnings: Beats Expectations
Liquidia ( NASDAQ:LQDA ) Full Year 2022 Results Key Financial Results Revenue: US$15.9m (up 24% from FY 2021). Net...
ZacksLiquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 47.06% and 46.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksLiquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Insiders saw their US$2.6m investment bump up to US$4.2m after Liquidia Corporation (NASDAQ:LQDA) soared 15% last week
Last week, Liquidia Corporation ( NASDAQ:LQDA ) insiders, who had purchased shares in the previous 12 months were...
ZacksStrength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength?
Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ZacksAre Medical Stocks Lagging Assertio (ASRT) This Year?
Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
ZacksWall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 153%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 153.2% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksIs Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year?
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.
ZacksLiquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksAre Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?
Here is how Acadia Healthcare (ACHC) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
- Simply Wall St.
Trade Alert: The CEO & Director Of Liquidia Corporation (NASDAQ:LQDA), Roger Jeffs, Has Just Spent US$244k Buying 2.6% More Shares
Potential Liquidia Corporation ( NASDAQ:LQDA ) shareholders may wish to note that the CEO & Director, Roger Jeffs...
- Simply Wall St.
Liquidia (NASDAQ:LQDA) Is Using Debt Safely
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
- Motley Fool
Why Liquidia Stock Rocketed Nearly 21% Higher Today
One of the more volatile healthcare stocks of recent days, Liquidia Technologies (NASDAQ: LQDA), had quite the up session on Friday. Investors lifted the share price of the drug developer by almost 21%, following a series of relatively small but confidence-boosting insider buys. Liquidia has been an up-and-down stock due to developments on the legal front, specifically a patent infringement dispute it was engaged in against plaintiff United Therapeutics (NASDAQ: UTHR).
ZacksWall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 136%: Here's is How to Trade
The mean of analysts' price targets for Liquidia Technologies, Inc. (LQDA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZacksIs Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?
Here is how Liquidia Technologies, Inc. (LQDA) and PolyPid Ltd. (PYPD) have performed compared to their sector so far this year.
ZacksFind Highly-Ranked Cheap Stocks Under $10 to Buy with this Screen
We used one of our Zacks screens to help show investors how to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying as we start to close out August.
ZacksHere's Why Liquidia Technologies, Inc. (LQDA) is a Great Momentum Stock to Buy
Does Liquidia Technologies, Inc. (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Motley Fool
Why Liquidia Shares Rose 18.4% on Monday
Shares of Liquidia Technologies (NASDAQ: LQDA), a biopharmaceutical company specializing in treatment of pulmonary arterial hypertension and other uses of its PRINT (Particle Replication In Non-Wetting Templates) technology, rose 18.4% on Monday. The stock closed at $7.30 on Friday, then rose to a high of $8.64 on Monday before falling to $8.39 at Monday's close. The stock has a 52-week low of $2.40 with a high of $8.79.
ZacksWall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 74%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 74.1% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.